

Jean Lachaine

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2773584/publications.pdf>

Version: 2024-02-01

49
papers

826
citations

516215

16
h-index

525886

27
g-index

50
all docs

50
docs citations

50
times ranked

1373
citing authors

#	ARTICLE	IF	CITATIONS
1	Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. <i>British Journal of Ophthalmology</i> , 2022, 106, 640-647.	2.1	10
2	Real-world evidence: a practical toolbox for collecting health state utilities. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 57-64.	0.6	0
3	The Impact of Hypoglycemia on Productivity Loss and Utility in Patients With Type 2 Diabetes Treated With Insulin in Real-world Canadian Practice: Protocol for a Prospective Study. <i>JMIR Research Protocols</i> , 2022, 11, e35461.	0.5	4
4	Healthcare resource utilization and costs associated with renal, bone and cardiovascular comorbidities among persons living with HIV compared to the general population in Quebec, Canada. <i>PLoS ONE</i> , 2022, 17, e0262645.	1.1	0
5	Economic Evaluation of a New Polygenic Risk Score to Predict Nephropathy in Adult Patients With Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2021, 45, 129-136.	0.4	8
6	Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada. <i>Current Oncology</i> , 2021, 28, 332-345.	0.9	7
7	Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization. <i>Journal of Cutaneous Medicine and Surgery</i> , 2020, 24, 573-587.	0.6	4
8	Review of real-world evidence studies in type 2 diabetes mellitus: Lack of good practices. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 372-379.	0.2	1
9	Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2019, 29, 730-739.	0.7	0
10	Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-14.	0.8	16
11	Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 287-301.	1.2	28
12	Alternatives to eye bank native tissue for corneal stromal replacement. <i>Progress in Retinal and Eye Research</i> , 2017, 59, 97-130.	7.3	75
13	Collaborative writing applications in healthcare: effects on professional practice and healthcare outcomes. <i>The Cochrane Library</i> , 2017, 2017, CD011388.	1.5	13
14	Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available. <i>Pharmacoeconomics</i> , 2016, 34, 889-900.	1.7	3
15	The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA. <i>Clinical Drug Investigation</i> , 2016, 36, 305-312.	1.1	12
16	Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD. <i>BMC Psychiatry</i> , 2016, 16, 11.	1.1	9
17	Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada. <i>Hematological Oncology</i> , 2015, 33, 229-238.	0.8	6
18	Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. <i>European Journal of Haematology</i> , 2015, 95, 218-229.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Cost-utility analysis of nonalcoholic steatohepatitis screening. <i>European Radiology</i> , 2015, 25, 3282-3294.	2.3	51
20	Implementation and Evaluation of a Wiki Involving Multiple Stakeholders Including Patients in the Promotion of Best Practices in Trauma Care: The WikiTrauma Interrupted Time Series Protocol. <i>JMIR Research Protocols</i> , 2015, 4, e21.	0.5	17
21	Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S40-7.	0.9	14
22	Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada. <i>Journal of Medical Economics</i> , 2014, 17, 296-304.	1.0	6
23	Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada. <i>BMC Psychiatry</i> , 2014, 14, 16.	1.1	10
24	The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. <i>European Journal of Health Economics</i> , 2014, 15, 791-800.	1.4	27
25	Treatment Patterns, Resource Use, and Economic Outcomes Associated with Atypical Antipsychotic Prescriptions in Children and Adolescents with Attention-Deficit Hyperactivity Disorder in Quebec. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 597-608.	0.9	13
26	Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in quebec. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2014, 23, 157-66.	0.7	10
27	Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. <i>BMC Gastroenterology</i> , 2013, 13, 23.	0.8	41
28	The Impact of Memantine and Cholinesterase Inhibitor Initiation for Alzheimer Disease on the Use of Antipsychotic Agents: Analysis Using the Régie de l'Assurance Maladie du Québec Database. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 195-200.	0.9	16
29	Cost-Effectiveness Of Arsenic Trioxide + All-Trans Retinoic Acid Compared With All-Trans Retinoic Acid + Idarubicin In The Treatment Of Newly Diagnosed Acute Promyelocytic Leukemia In Canada. <i>Blood</i> , 2013, 122, 1677-1677.	0.6	0
30	Cost-Effectiveness Of Arsenic Trioxide In The Treatment Of Relapsed/Refractory Acute Promyelocytic Leukemia In Canada. <i>Blood</i> , 2013, 122, 5603-5603.	0.6	0
31	Treatment Patterns, Adherence, and Persistence in ADHD: A Canadian Perspective. <i>Postgraduate Medicine</i> , 2012, 124, 139-148.	0.9	42
32	Economic Evaluation of Dexmedetomidine Relative to Midazolam for Sedation in the Intensive Care Unit. <i>Canadian Journal of Hospital Pharmacy</i> , 2012, 65, 103-10.	0.1	27
33	A Proposed Framework for Formulary Listing in Low-Income Countries. <i>Pharmaceutical Medicine</i> , 2011, 25, 71-82.	1.0	8
34	Economic Evaluation of the Impact of Memantine on Time to Nursing Home Admission in the Treatment of Alzheimer Disease. <i>Canadian Journal of Psychiatry</i> , 2011, 56, 596-604.	0.9	22
35	Use, tolerability and compliance of spironolactone in the treatment of heart failure. <i>BMC Clinical Pharmacology</i> , 2011, 11, 4.	2.5	28
36	Clinical and Economic Characteristics of Patients With Fibromyalgia Syndrome. <i>Clinical Journal of Pain</i> , 2010, 26, 284-290.	0.8	106

#	ARTICLE	IF	CITATIONS
37	Choices, persistence and adherence to antihypertensive agents: Evidence from RAMQ data. Canadian Journal of Cardiology, 2008, 24, 269-273.	0.8	22
38	Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. Canadian Journal of Ophthalmology, 2008, 43, 33-41.	0.4	15
39	A Model for Assessing the Cost-Effectiveness of Atorvastatin and Simvastatin in Achieving Canadian Low-Density Lipoprotein Cholesterol Targets. Clinical Therapeutics, 2007, 29, 519-528.	1.1	9
40	Painful Neuropathic Disorders: An Analysis of the Régie De L'Assurance Maladie du Québec Database. Pain Research and Management, 2007, 12, 31-37.	0.7	32
41	Therapeutic Options for the Prevention and Treatment of Postoperative Nausea and Vomiting. Pharmacoeconomics, 2006, 24, 955-970.	1.7	9
42	Persistence and adherence to cholesterol lowering agents: Evidence from Régie de l'Assurance Maladie du Québec data. American Heart Journal, 2006, 152, 164-169.	1.2	34
43	Chemotherapy-Induced Emesis: Quality of Life and Economic Impact in the Context of Current Practice in Canada. Supportive Cancer Therapy, 2005, 2, 181-187.	0.3	37
44	Persistence and adherence to antihypertensive agents. American Journal of Hypertension, 2004, 17, S114-S115.	1.0	0
45	Defining Monetary Values for Quality of Life Improvements. Pharmacoeconomics, 2003, 21, 865-874.	1.7	3
46	Cost-effectiveness of antiemetics use during cancer chemotherapy. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 263-272.	0.7	3
47	Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy. American Journal of Health-System Pharmacy, 2002, 59, 1837-1846.	0.5	6
48	Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer. Critical Reviews in Oncology/Hematology, 1999, 32, 105-112.	2.0	13
49	Economic Evaluation of Antibacterials in the Treatment of Acute Sinusitis. Pharmacoeconomics, 1999, 15, 97-113.	1.7	7